Accesso libero

The effects of simvastatin and fenofibrate on malondialdehyde and reduced glutathione concentrations in the plasma, liver, and brain of normolipidaemic and hyperlipidaemic rats

Antonija Vukšić
Antonija Vukšić
, 
Dubravka Rašić
Dubravka Rašić
, 
Suzana Žunec
Suzana Žunec
, 
Tamara Božina
Tamara Božina
, 
Paško Konjevoda
Paško Konjevoda
, 
Jasna Lovrić
Jasna Lovrić
, 
Marinko Bilušić
Marinko Bilušić
 e 
Vlasta Bradamante
Vlasta Bradamante
   | 04 apr 2023
Archives of Industrial Hygiene and Toxicology's Cover Image
INFORMAZIONI SU QUESTO ARTICOLO
Articolo precedente
Articolo Successivo
Cita
Article Category: Original article
Pubblicato online: 04 apr 2023
Pagine: 34 - 41
Ricevuto: 01 dic 2022
Accettato: 01 mar 2023
DOI: https://doi.org/10.2478/aiht-2023-74-3697
© 2023 Antonija Vukšić et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

The effects of simvastatin (10 mg/kg and 50 mg/kg daily for 3 weeks) on MDA and GSH levels in the plasma, liver, and brain of normolipidaemic rats

Variable Source Controla Simvastatina(10 mg/kg/day) P valueb(95 % CI)c Controla Simvastatina(50 mg/kg/day) P valueb(95 % CI)c
MDA (μmol/L) Plasma 0.26±0.051(n=8) 0.24±0.046(n=8) 0.471(-0.05–0.08) 0.30±0.236(n=7) 0.24±0.036(n=6) 0.044(-0.14–0.06)
Liver 105.2±15.12(n=6) 92.3±19.26(n=10) 0.166(-33.31–6.32) 103.6±17.94(n=8) 104.8±22.54(n=8) 0.909(-20.65–23.04)
Brain 2.67±0.204(n=8) 1.11±0.231(n=10) <0.001(-1.77–1.33) 2.28±0.508(n=8) 1.80±0.218(n=6) 0.050(-0.97–0.01)
GSH (μg/mL) Plasma 57.3±17.68(n=6) 47.4±15.81(n=9) 0.324(-30.81–10.96) 51.0±17.68(n=8) 47.7±26.80(n=7) 0.778(-28.32–21.61)
Liver 133.5±21.24(n=6) 218.1±43.03(n=5) 0.002(39.80–129.6) 229.0±36.05(n=6) 258.0±135.2(n=6) 0.623(-96.57–43.02)
Brain 17.2±4.61(n=8) 22.1±9.08(n=10) 0.179(-2.52–12.47) 20.2±4.23(n=8) 23.6±5.01(n=9) 0.152(-1.41–8.24)

The effects of fenofibrate (30 mg/kg and 50 mg/kg daily for 3 weeks) on MDA and GSH levels in the plasma, liver, and brain of normolipidaemic rats

Variable Source Controla Fenofibratea(30 mg/kg/day) P valueb(95 % CI)c Controla Fenofibratea(50 mg/kg/day) P valueb(95 % CI)c
MDA (μmol/L) Plasma 0.33±0.127(n=5) 0.20±0.033(n=8) 0.017(-0.23–0.03) 0.31±0.048(n=8) 0.18±0.022(n=8) <0.001(-0.17–0.08)
Liver 62.2±14.43(n=7) 62.4±15.37(n=10) 0.971(-34.18–14.22) 85.0±10.70(n=8) 71.1±11.95(n=8) 0.188(-23.18–7.57)
Brain 3.51±0.596(n=8) 3.30±0.40(n=10) 0.404(-0.69–0.29) 2.89±1.018(n=8) 2.20±0.13(n=7) 0.120(-1.30–0.09)
GSH (μ/mL) Plasma 69.6±20.85(n=5) 76.5±15.63(n=4) 0.602(-22.93–36.68) 70.4±12.23(n=6) 92.4±18.32(n=7) 0.030(2.60–41.41)
Liver 71.8±36.16(n=8) 33.3±17.71(n=9) 0.013(-67.33–9.57) 72.6±16.31(n=6) 29.2±10.27(n=10) <0.001(-57.51–29.24)
Brain 16.7±2.54(n=7) 15.2±3.54(n=9) 0.349(-4.95–1.87) 20.6±5.58(n=8) 23.5±2.57(n=10) 0.169(-1.34–7.03)

The effects of simvastatin (50 mg/kg daily for 3 weeks) and fenofibrate (30 mg/kg daily for 3 weeks) on MDA and GSH levels in the plasma, liver, and brain of hyperlipidaemic rats

Variable Source Controla Simvastatina(50 mg/kg/day) P valueb(95 % CI)c Fenofibratea(30 mg/kg/day) P valueb(95 % CI)c
MDA (μmol/L) Plasma 0.39±0.114(n=6) 0.40±0.036(n=6) 0.960(-0.11–0.09) 0.26±0.036(n=7) 0.009(0.04–0.24)
Liver 92.1±30.00(n=6) 100.4±19.45(n=6) 0.828(-46.89–30.43) 82.8±31.26(n=7) 0.774(-27.96–46.55)
Brain 9.7±1.67(n=6) 8.6±2.42(n=6) 0.641(-2.32–4.61) 13.5±3.08(n=6) 0.032(-7.26–0.33)
GSH (μ/mL) Plasma 251.7±127.4(n=4) 224.2±57.58(n=5) 0.845(-117.2–172.2) 304.6±0.033(n=4) 0.593(-205.5–99.61)
Liver 59.4±22.00(n=6) 33.0±24.04(n=5) 0.045(0.57–52.34) 12.2±5.98(n=8) 0.001(24.13–70.30)
Brain 8.9±1.73(n=6) 9.1±1.80(n=6) 0.876(-3.26–2.28) 9.1±2.30(n=7) 0.847(-3.19–2.14)
eISSN:
1848-6312
Lingue:
Inglese, Slovenian
Frequenza di pubblicazione:
4 volte all'anno
Argomenti della rivista:
Medicine, Basic Medical Science, other
Feed RSS della rivista